Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognosis in N2 NSCLC.

Godehard Friedel1, Volker Steger, Thomas Kyriss

  • 1Department of Thoracic Surgery, Schillerhoehe Hospital, Solitudestrasse 18, D-70839 Gerlingen, Germany. Friedel@klinik-schillerhoehe.de

Lung Cancer (Amsterdam, Netherlands)
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive Aortic Regurgitation After Impella Bridge-to-LVAD: A Two-Year Cohort Analysis.

Biomedicines·2026
Same author

[Non-small cell lung cancer - surgical treatment options in the early stages].

Deutsche medizinische Wochenschrift (1946)·2026
Same author

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS).

Journal of cancer research and clinical oncology·2026
Same author

Osteosarcoma of the Diaphysis: A Report from the Cooperative Osteosarcoma Study Group (COSS).

Anticancer research·2025
Same author

Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group (COSS).

Cancer medicine·2025

Prognosis for stage III N2 bronchogenic carcinoma is poor, with survival between 0-5%. Complete lymphadenectomy is crucial for survival and accurate staging, with lymph node count being a key prognostic factor.

Area of Science:

  • Thoracic oncology
  • Surgical oncology
  • Pulmonary medicine

Background:

  • Stage III N2 bronchogenic carcinoma carries a poor prognosis, with 5-year survival rates of 0-5%.
  • Lymph node involvement is the primary prognostic determinant.
  • Accurate staging is critical for treatment planning, especially before neoadjuvant therapy.

Purpose of the Study:

  • To emphasize the prognostic significance of lymph node involvement in stage III N2 lung cancer.
  • To highlight the importance of complete lymphadenectomy for survival and accurate staging.
  • To underscore the need for detailed lymph node anatomy knowledge and documentation.

Main Methods:

  • Review of existing literature on prognostic factors in stage III N2 lung cancer.
  • Analysis of the impact of lymphadenectomy extent (complete vs. sampling) on survival.

Related Experiment Videos

  • Evaluation of lymph node count as a prognostic indicator.

    • Main Results:

    • Complete lymphadenectomy significantly improves long-term survival compared to lymph node sampling.
    • The number of involved lymph nodes is a critical prognostic factor.
    • Accurate pathological examination and documentation of examined lymph nodes are essential for staging and comparison.

    Conclusions:

    • Complete lymphadenectomy is necessary for accurate staging and improved survival in stage III N2 lung cancer.
    • The number of involved lymph nodes and detailed lymph node mapping are vital prognostic indicators.
    • While molecular markers are under investigation, their clinical relevance in N2 staging is not yet established.